Renee Floresta-Chan, APRN
Family · Sun City Center, FLNPI 1871119719
Payments from drug & device makers
Across 252 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$524
- Lilly USA, LLC$496
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$379
- Amgen$355
- Bayer$318
- Pfizer$295
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,713100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $524 |
| Lilly USA, LLC | 27 | $496 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $379 |
| Amgen | 26 | $355 |
| Bayer | 13 | $318 |
| Pfizer | 15 | $295 |
| Sumitomo Pharma America, Inc. | 17 | $263 |
| AstraZeneca | 14 | $220 |
| Novo Nordisk | 8 | $178 |
| Otsuka America Pharmaceutical, Inc. | 8 | $177 |
| Astellas Pharma US Inc | 7 | $151 |
| GSK | 9 | $148 |
| Exact Sciences | 6 | $136 |
| Dexcom, Inc. | 6 | $134 |
| Mylan Specialty L.p. | 5 | $131 |
| Idorsia Pharmaceuticals US Inc | 5 | $95 |
| Esperion Therapeutics, Inc. | 4 | $76 |
| Sunovion Pharmaceuticals Inc. | 6 | $74 |
| Merck | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $67 |
| Amarin Pharma, Inc. | 2 | $46 |
| Si-bone, Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Biogen | 1 | $30 |
| Lundbeck LLC | 2 | $29 |
| Nevro Corp. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $21 |
| Convatec Inc. | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Smith+Nephew | 1 | $15 |
| Corium, LLC | 1 | $15 |
| Saluda Medical Americas, Inc. | 1 | $15 |
How this compares
$4,713 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $71,119 |
| OzempicSemaglutide | 33 | $46,956 |
| MounjaroTirzepatide | 26 | $41,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $29,343 |
| EntrestoSacubitril/Valsartan | 12 | $20,973 |
| MyrbetriqMirabegron | 16 | $17,047 |
| FarxigaDapagliflozin Propanediol | 11 | $16,112 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,098 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 14 | $1,977 |
| Novolog FlexpenInsulin Aspart | 12 | $1,834 |
| Duloxetine Hcl | 44 | $1,692 |
| Omeprazole | 101 | $1,540 |
| Gabapentin | 75 | $1,527 |
| SynthroidLevothyroxine Sodium | 17 | $1,461 |
| Atorvastatin Calcium | 180 | $1,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $295 | $71,11956 claims |
| Novo NordiskOzempic | $178 | $46,95633 claims |
| Lilly USA, LLCMounjaro | $496 | $41,71026 claims |
| GSKTrelegy Ellipta | $148 | $29,34327 claims |
| Astellas Pharma US IncMyrbetriq | $151 | $17,04716 claims |
| AstraZenecaFarxiga | $220 | $16,11211 claims |
| AbbVieSynthroid | $524 | $1,46117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Sun City Center
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.